Jessica Tassan
Stock Analyst at Piper Sandler
(1.06)
# 3,972
Out of 5,182 analysts
87
Total ratings
29.33%
Success rate
-13.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVS CVS Health | Maintains: Overweight | $101 → $99 | $78.36 | +26.34% | 7 | Mar 31, 2026 | |
| CI The Cigna Group | Reiterates: Overweight | $374 → $370 | $282.58 | +30.94% | 5 | Mar 3, 2026 | |
| TDOC Teladoc Health | Reiterates: Overweight | $12 → $9 | $5.85 | +53.85% | 7 | Feb 26, 2026 | |
| DOCS Doximity | Maintains: Overweight | $40 → $42 | $24.66 | +70.32% | 6 | Feb 20, 2026 | |
| OMCL Omnicell | Reiterates: Overweight | $63 → $49 | $37.63 | +30.22% | 5 | Feb 6, 2026 | |
| HNGE Hinge Health | Maintains: Overweight | $71 → $60 | $45.03 | +33.24% | 3 | Jan 9, 2026 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $20 → $30 | $20.95 | +43.20% | 6 | Jan 6, 2026 | |
| OSCR Oscar Health | Upgrades: Overweight | $13 → $25 | $17.18 | +45.52% | 7 | Nov 26, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $423 → $417 | $354.69 | +17.57% | 9 | Oct 29, 2025 | |
| PHR Phreesia | Maintains: Overweight | $33 → $34 | $9.62 | +253.43% | 6 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $3.47 | +418.73% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.37 | +191.97% | 12 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $86 | $24.22 | +255.08% | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $288 → $272 | $223.62 | +21.63% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 → $8 | $6.14 | +30.29% | 3 | May 23, 2025 |
CVS Health
Mar 31, 2026
Maintains: Overweight
Price Target: $101 → $99
Current: $78.36
Upside: +26.34%
The Cigna Group
Mar 3, 2026
Reiterates: Overweight
Price Target: $374 → $370
Current: $282.58
Upside: +30.94%
Teladoc Health
Feb 26, 2026
Reiterates: Overweight
Price Target: $12 → $9
Current: $5.85
Upside: +53.85%
Doximity
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $24.66
Upside: +70.32%
Omnicell
Feb 6, 2026
Reiterates: Overweight
Price Target: $63 → $49
Current: $37.63
Upside: +30.22%
Hinge Health
Jan 9, 2026
Maintains: Overweight
Price Target: $71 → $60
Current: $45.03
Upside: +33.24%
Alignment Healthcare
Jan 6, 2026
Maintains: Overweight
Price Target: $20 → $30
Current: $20.95
Upside: +43.20%
Oscar Health
Nov 26, 2025
Upgrades: Overweight
Price Target: $13 → $25
Current: $17.18
Upside: +45.52%
UnitedHealth Group
Oct 29, 2025
Maintains: Overweight
Price Target: $423 → $417
Current: $354.69
Upside: +17.57%
Phreesia
Sep 5, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $9.62
Upside: +253.43%
Aug 28, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $3.47
Upside: +418.73%
Aug 27, 2025
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.37
Upside: +191.97%
Aug 15, 2025
Maintains: Overweight
Price Target: $44 → $86
Current: $24.22
Upside: +255.08%
Jul 31, 2025
Maintains: Neutral
Price Target: $288 → $272
Current: $223.62
Upside: +21.63%
May 23, 2025
Reiterates: Neutral
Price Target: $10 → $8
Current: $6.14
Upside: +30.29%